Michael John Tomsicek
CIK: 0001570392
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 17, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares- - Jun 10, 2026MIST
Milestone Pharmaceuticals Inc.
Award(A)DirectStock Option (right to buy)
77K shares- - May 18, 2026ACRV
Acrivon Therapeutics, Inc.
Award(A)Direct9.4K shares- - Jun 13, 2025ACRV
Acrivon Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.3K shares- - Jun 10, 2025MIST
Milestone Pharmaceuticals Inc.
Award(A)DirectStock Option (right to buy)
40K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| Jun 10, 2026 |  MIST Milestone Pharmaceuticals Inc. | Award(A) Stock Option (right to buy) | 77,000 | - | - | Direct |
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc. | Award(A) | 9,366 | - | $0 | Direct |
| Jun 13, 2025 | ACRV Acrivon Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| Jun 10, 2025 | MIST Milestone Pharmaceuticals Inc. | Award(A) Stock Option (right to buy) | 40,000 | - | - | Direct |
1-5 of 5 transactions
About TOMSICEK MICHAEL JOHN
TOMSICEK MICHAEL JOHN (SEC CIK 0001570392) files insider reports with the SEC as Director of Acrivon Therapeutics, Inc. (ACRV) and Director of Milestone Pharmaceuticals Inc. (MIST).
Signal8 holds 5 ownership filings by TOMSICEK MICHAEL JOHN, all Form 4s, filed between Jun 12, 2025 and Jun 22, 2026. Those filings report 5 transactions, from Jun 10, 2025 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on TOMSICEK MICHAEL JOHN's filings is in MONTREAL.
Recent filings by TOMSICEK MICHAEL JOHN
- Jun 17, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
- Jun 10, 2026: Grant or award of MIST derivative securities (Form 4, code A).
- May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
- Jun 13, 2025: Grant or award of ACRV derivative securities (Form 4, code A).
- Jun 10, 2025: Grant or award of MIST derivative securities (Form 4, code A).
Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)
- Miller Mary, Chief Legal Officer
- Levin Michaela, Chief Business Officer
- Blume-Jensen Peter, President and CEO
- Peterson Katharine, Chief Accounting Officer
- Gamelin Erick, Chief Development Officer
- Devroe Eric, Chief Operating Officer